The Nuclear Boom Is Real. These 3 Stocks Are the Smartest Long-Term Buys.

The article argues that nuclear power demand is accelerating, with Cameco estimating uranium supply will be outstripped in the 2030s as 72 reactors are under construction and older units are being restarted or extended. It highlights Cameco and Brookfield Renewable as lower-risk ways to play the theme, while NuScale and Oklo are framed as high-risk, high-reward small modular reactor bets. Brookfield’s 4.5% yield and Westinghouse exposure are presented as defensive advantages, but the piece is mainly an opinion-driven sector overview rather than a catalyst.

Analysis

The market is likely underpricing the duration mismatch in this theme: the near-term winners are not the speculative reactor designers, but the enablers with regulatory permits, fuel contracts, and balance-sheet capacity to finance multi-year buildouts. That favors CCJ and, to a lesser extent, BEP through its Westinghouse exposure and income wrapper, while SMR/OKLO remain binary on demonstration risk and capital intensity. The second-order effect is that any credible acceleration in deployment should widen the valuation gap between “picks-and-shovels” cash flows and pre-revenue technology names, especially if higher-for-longer rates keep discounting pressure on distant equity stories.

The key catalyst path is not new reactor announcements per se, but proof of schedule discipline: grid connection, permitting, and standardized construction timelines. If small modular reactors fail to show repeatable execution over the next 12-24 months, enthusiasm can rotate back into uranium miners and engineering/service beneficiaries that monetize volume growth without needing technology adoption to be perfect. Conversely, a single successful deployment could re-rate the entire SMR basket sharply, but that upside is likely concentrated in the first mover rather than distributed evenly across the group.

The contrarian miss is that a “nuclear renaissance” can be bullish for the supply chain without being bullish for the newest entrants. In a capital-constrained environment, utilities and governments will likely prefer proven fuel and services providers before committing to unproven reactor IP, which makes the adoption curve slower but more profitable for incumbents. That supports a barbell: own the cash-generative infrastructure/uranium layer, fade the most expensive pre-commercial optionality unless execution risk is already priced in.

Key Decisions for Investors

• Long CCJ on 6-12 month horizon; use pullbacks to add, targeting continued uranium repricing as supply discipline and reactor restarts tighten the market. Risk/reward remains favorable as the stock monetizes the theme without needing SMR adoption to work.
• Long BEP for 12 months as a lower-beta way to own nuclear adjacency plus yield; the income stream should cushion downside if the SMR narrative stalls. Use as a defensive pairing against more speculative clean-tech exposure.
• Pair trade: long CCJ / short OKLO for 3-6 months to express the view that fuel scarcity and existing contracts will monetize before pre-commercial reactor economics. This isolates execution risk and should work unless OKLO secures a major financing or utility partnership catalyst.
• Tactical long SMR only via call spreads, 6-9 months out, sized small; the upside is large if a credible deployment milestone lands, but dilution and schedule slippage make outright equity exposure unattractive. Cap risk to premium paid.
• Trim or avoid chasing strength in the pre-revenue names after sharp rallies; wait for either a financing event or a real operating milestone before adding. The best risk/reward is likely in the second derivative beneficiaries, not the headline names.